SeaSpine Reports Granting of Inducement Awards
SeaSpine Holdings Corporation (NASDAQ: SPNE) has issued inducement equity awards to Beau Standish and 44 non-executive employees following the acquisition of 7D Surgical.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SeaSpine Holdings Corporation (NASDAQ: SPNE) has issued inducement equity awards to Beau Standish and 44 non-executive employees following the acquisition of 7D Surgical. The awards, approved by the independent compensation committee, involve options to purchase 544,150 shares at an exercise price of $19.99, equal to the closing price on June 2, 2021. These options have an 8-year term and will vest incrementally over the next few years, enhancing employee retention and aligning interests with company growth.
Positive
- Issuance of inducement awards to 44 non-executive employees can enhance retention and motivate the workforce.
- Acquisition of 7D Surgical may expand SeaSpine's portfolio and market presence.
Negative
- None.
Details
News Market Reaction – SPNE
The recorded move for SPNE in the trading session of this news was -2.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has issued inducement awards to Beau Standish and 44 non-executive employees in connection with the closing of its acquisition of 7D Surgical.
The awards were made on June 2, 2021 under SeaSpine’s 2020 Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of SeaSpine. The inducement awards consist of options to purchase an aggregate of 544,150 shares of SeaSpine common stock. The exercise price of the options was
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products and enabling technologies that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants and software product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
Investor Relations Contact
Leigh Salvo
(415) 937-5402
ir@seaspine.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.